WILLOW BIOSCIENCES ANNOUNCES ANNUAL GENERAL AND SPECIAL MEETING VOTING RESULTS
PR Newswire
SUNNYVALE, Calif., April 25, 2025
SUNNYVALE, Calif., April 25, 2025 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF) is pleased to announce the voting results from its annual general and special meeting of shareholders held on April 25, 2025 (the "Meeting"). A total of 59,214,893 common shares, representing approximately 40.88% of the Company's issued and outstanding shares were represented at the meeting.
The shareholders approved the setting of the number of directors of Willow at 5 directors, and the following nominees were elected as directors of Willow for the ensuing year with the specific voting results being as follows:
Votes For Votes Withheld ----------------- ------------------ ----------------- Director # % # % ----------------- ---------- ------ --------- ------ Dr. Chris Savile 46,902,346 88.3 % 6,234,676 11.7 % ----------------- ---------- ------ --------- ------ Dr. Jim Lalonde 46,965,380 88.4 % 6,171,642 11.6 % ----------------- ---------- ------ --------- ------ Donald Archibald 44,900,287 84.5 % 8,236,735 15.5 % ----------------- ---------- ------ --------- ------ Raffi Asadorian 46,963,057 88.4 % 6,173,965 11.6 % ----------------- ---------- ------ --------- ------ Al Foreman 46,900,723 88.3 % 6,236,299 11.7 % ----------------- ---------- ------ --------- ------
In addition, shareholders approved the below matters. The resolutions approving the below matters may be viewed in full in the Company's management information circular dated March 26, 2025 (the "Information Circular").
Votes For ---------------------------------------------------------- ------------------ Director # % ---------------------------------------------------------- ---------- ------ Appointment of KPMG LLP as the Company's auditor for the ensuring year 51,882,364 87.6 % ---------------------------------------------------------- ---------- ------ The proposed sale of the shares of Epimeron USA, Inc., the Corporation's wholly-owned subsidiary, as more particularly described in the Information Circular 46,996,397 88.4 % ---------------------------------------------------------- ---------- ------ To authorize the Corporation's board of directors, at its sole discretion, to amend the Articles of the Corporation to change its name from "Willow Biosciences Inc." to "2482118 Alberta Ltd.", or such other name as may be approved by the Board, as more particularly described in the Information Circular. 48,853,362 82.5 % ---------------------------------------------------------- ---------- ------
For complete voting results on all matters approved at the Meeting, please see the Company's Report of Voting Results dated April 25, 2025, available on SEDAR+ at www.sedarplus.ca.
About Willow Biosciences Inc.
Willow develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Willow's FutureGrown$(TM)$ biotechnology platform allows large-scale production with sustainability at its core. Willow's R&D team has a proven track record of developing and commercializing bio-based manufacturing processes and products to benefit our B2B partners and their customers.
For more information, visit www.willowbio.com or contact:
Travis Doupe
Chief Financial Officer
E: info@willowbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/willow-biosciences-announces-annual-general-and-special-meeting-voting-results-302438831.html
SOURCE Willow Biosciences Inc.
(END) Dow Jones Newswires
April 25, 2025 19:22 ET (23:22 GMT)
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。